2014
DOI: 10.1016/s0140-6736(14)60920-x
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

6
142
0
4

Year Published

2015
2015
2021
2021

Publication Types

Select...
8

Relationship

4
4

Authors

Journals

citations
Cited by 160 publications
(152 citation statements)
references
References 37 publications
6
142
0
4
Order By: Relevance
“…This study included a subset of women with a history of HPV infection or disease, and as such, supported the contention that women older than 25 y can also benefit from HPV vaccination when they have been previously exposed to HPV. 41 Furthermore, decreasing efficacy with age was observed in the ITT population in the Costa Rica HPV trial, where the efficacy fell from 68.9% (95% CI 53.1-79.9) in women aged 18-19 y, to 21.8% (95% CI: 16.9, 47.9) in 24-25 year-olds. 42 Similar findings were observed for the quadrivalent HPV vaccine in a study including over 2.2 million females aged 10-44 y, where increased vaccine effectiveness with decreasing age was noted.…”
Section: Human Papillomavirus (Hpv) Vaccinationmentioning
confidence: 96%
See 1 more Smart Citation
“…This study included a subset of women with a history of HPV infection or disease, and as such, supported the contention that women older than 25 y can also benefit from HPV vaccination when they have been previously exposed to HPV. 41 Furthermore, decreasing efficacy with age was observed in the ITT population in the Costa Rica HPV trial, where the efficacy fell from 68.9% (95% CI 53.1-79.9) in women aged 18-19 y, to 21.8% (95% CI: 16.9, 47.9) in 24-25 year-olds. 42 Similar findings were observed for the quadrivalent HPV vaccine in a study including over 2.2 million females aged 10-44 y, where increased vaccine effectiveness with decreasing age was noted.…”
Section: Human Papillomavirus (Hpv) Vaccinationmentioning
confidence: 96%
“…[41][42][43][44] However, episodes of mass psychogenic syndrome have been reported and it is therefore important to carefully plan the setting where mass vaccination campaigns will be implemented.…”
Section: Human Papillomavirus (Hpv) Vaccinationmentioning
confidence: 99%
“…Skinner and colleagues affirm that prophylactic HPV vaccination is safe and prevents the acquisition of target HPV genotypes at any age, and that woman of any age could gain some potential benefit from HPV vaccination. 18 Vaccine resistance…”
Section: Vaccination Beyond 26 Years and In Hpv Infected Populationmentioning
confidence: 99%
“…5 A infeção pelo HPV é condição necessária na quase totalidade dos casos de CCU, [5][6][7][8][9][10] existindo mais de 100 genótipos do HPV estudados; 90% dos casos de CCU são provocados pelos genótipos de alto risco (oncogénicos) 16,18,45,31,33,52, 58 e 35. 5,[10][11][12][13][14] A infeção pelos genótipos 16 e 18 está na origem da grande maioria dos casos de CCU Revista Científica da Ordem dos Médicos www.actamedicaportuguesa.com Ribeiro JP, et al Eficácia das vacinas contra o HPV nas mulheres com mais de 24 anos na prevenção do CCU, Acta Med Port 2016 Jun;29 (6): [401][402][403][404][405][406][407][408] -mais de 70% dos casos, 5,6,10,[14][15][16][17] enquanto aproximadamente 10% são consequência da infeção pelos genótipos 45 e 31, 15 e os restantes são causados por outros genóti-pos oncogénicos. Esta infeção é uma doença sexualmente transmissível, representando uma das mais comuns, 11,12,14 o genótipo 16 é o mais prevalente, 12 apesar de existir variação geográfica na prevalência dos genótipos.…”
Section: Introductionunclassified
“…18,19 A maioria das infeções por HPV é transitória, 6,15 ocorrendo resolução espontânea em 90% dos casos após dois anos, 15 que, no entanto, não confere imunidade contra a infeção pelo vírus. 6,9,12,13,15,16 A eficácia das vacinas contra o HPV nas mulheres até aos 25 anos de idade está bem comprovada, 10,11,16,17,19 porém, a eficácia em idades superiores ainda não está totalmente estabelecida e existem dúvidas quanto à sua utilização.…”
Section: Introductionunclassified